[
  {
    "ts": null,
    "headline": "NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth",
    "url": "https://finnhub.io/api/news?id=d3749e1acfc6e1ca9a311738957e5d298a7038b14236e74c88631a7c02bb8675",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755121865,
      "headline": "NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know",
      "id": 136345175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth",
      "url": "https://finnhub.io/api/news?id=d3749e1acfc6e1ca9a311738957e5d298a7038b14236e74c88631a7c02bb8675"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call",
    "summary": "Revvity’s second quarter results were met with a negative market reaction, as new regulatory headwinds in China’s diagnostics sector weighed on investor sentiment. Management attributed the quarter’s performance to robust growth in its Life Sciences division, particularly its Signals software franchise and sustained demand from pharmaceutical and biotech clients. CEO Prahlad Singh described the operating environment as “dynamic” and noted that, despite challenges, Revvity’s portfolio delivered 3",
    "url": "https://finnhub.io/api/news?id=322e7776f2a306e6be44c8d743b412e61a2a856ffbe31dcd71c4f42447c918d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058991,
      "headline": "The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call",
      "id": 136328926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "Revvity’s second quarter results were met with a negative market reaction, as new regulatory headwinds in China’s diagnostics sector weighed on investor sentiment. Management attributed the quarter’s performance to robust growth in its Life Sciences division, particularly its Signals software franchise and sustained demand from pharmaceutical and biotech clients. CEO Prahlad Singh described the operating environment as “dynamic” and noted that, despite challenges, Revvity’s portfolio delivered 3",
      "url": "https://finnhub.io/api/news?id=322e7776f2a306e6be44c8d743b412e61a2a856ffbe31dcd71c4f42447c918d9"
    }
  },
  {
    "ts": null,
    "headline": "RVTY Q2 Deep Dive: China Diagnostics Headwinds Offset Life Sciences Stability",
    "summary": "Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.1% year on year to $720.3 million. The company expects the full year’s revenue to be around $2.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.18 per share was 3.4% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=2c4942673b1d8c6d2b03a3e6884c7c0bd5e8fcc39a7ed9edd46878154a756489",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058907,
      "headline": "RVTY Q2 Deep Dive: China Diagnostics Headwinds Offset Life Sciences Stability",
      "id": 136328927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.1% year on year to $720.3 million. The company expects the full year’s revenue to be around $2.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.18 per share was 3.4% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=2c4942673b1d8c6d2b03a3e6884c7c0bd5e8fcc39a7ed9edd46878154a756489"
    }
  }
]